<DOC>
	<DOCNO>NCT02647086</DOCNO>
	<brief_summary>This open-label , single-sequence DDI study design examine effect dupilumab pharmacokinetics select cytochrome P450 substrate adult patient moderate severe AD . The study consist screen period ( day -35 -2 ) , study period 1 ( day -1 7 ) , study period 2 ( day 8 50 ) , follow-up period ( day 51 135 [ end study ] ) . Following completion study period 2 ( Day 50 ) , patient give option enroll Open-Label Extension ( OLE ) study R668-AD-1225 . Patients decline follow next 12 week ( Day 135 ) .</brief_summary>
	<brief_title>Open Label , Drug-Drug Interaction ( DDI ) Study Dupilumab ( REGN668/SAR231893 ) Patients With Moderate Severe Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Male female patient , age 18 year old 2 . Diagnosis Chronic AD , define diagnosis AD least 3 year screen visit 3 . Eczema Area Severity Index ( EASI ) score ≥16 screen baseline visit 4 . Investigator 's Global Assessment ( IGA ) score ≥3 ( 0 4 IGA scale ) screen baseline visit 5 . ≥10 % Body Surface Area ( BSA ) AD involvement screen baseline visit 6 . Patients documented recent history ( within 6 month screen visit ) inadequate response outpatient treatment topical medication , topical treatment otherwise medically inadvisable ( eg , important side effect safety risk ) 7 . Provide sign informed consent 1 . Prior participation dupilumab clinical trial 2 . The use follow treatment within 4 week baseline visit : Systemic corticosteroid Immunosuppressive/immunomodulating drug Phototherapy AD 3 . Administration , within 14 day baseline within period 5 time elimination halflife medication baseline , whichever longer , medication know inducer inhibitor either one follow CYP enzyme : CYP3A , CYP2C19 , CYP2C9 , CYD2D6 , CYP1A2 . Patients medication time screen safely take medication exclude study . 4 . Any contraindication one follow drug , accord applicable labeling : Midazolam Omeprazole Warfarin Caffeine Metoprolol 5 . Consumption 1 follow food item and/ beverage within 1 week prior baseline : Grapefruit grapefruit juice , apple apple juice , orange orange juice , lemon lemon juice , lime lime juice Vegetables mustard green family ( eg , broccoli ) Charbroiled meat Caffeinated beverage , food drug contain caffeine Patients willing abstain consumption food item and/or beverage certain period study also exclude 6 . History excessive consumption beverage contain caffeine ( 4 cup glass per day ) . Patients willing abstain consumption caffeine certain period study also exclude 7 . History presence alcohol drug abuse within last 2 year 8 . History smoking within last 2 year 9 . Poor metabolizers CYP2C9 , CYP2C19 , CYP2D6 base genotyping 10 . Presence one follow lab abnormality screen : Platelet count ≤100 x 10^3/µL Neutrophils ≤1 x 10^3/µL Creatinine phosphokinase ( CPK ) &gt; 10 x upper limit normal ( ULN ) International normalize ratio ( INR ) ≥2 11 . Active chronic acute infection require treatment systemic antibiotic , antiviral , antiprotozoal , antifungal within 2 week screen visit , superficial skin infection within 1 week screen visit 12 . Known suspected immunodeficiency , include history invasive opportunistic infection ( eg , tuberculosis , histoplasmosis , listeriosis , coccidioidomycosis , pneumocystosis , aspergillosis ) despite infection resolution , otherwise recurrent infection abnormal frequency prolong duration suggest immune compromise status , judge investigator 13 . History human immunodeficiency virus ( HIV ) infection positive HIV serology screen 14 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) , hepatitis C antibody ( Hep C Ab ) screen visit . NOTE : Patients HBsAg negative HBsAb positive consider immune natural infection clear vaccinated hepatitis B . Therefore , acceptable study . 15 . History malignancy within 5 year baseline visit , except completely treat situ carcinoma cervix , completely treat resolve nonmetastatic squamous basal cell carcinoma skin 16 . History clinical endoparasitosis ( ie , helminth infection ) within 12 month baseline visit , high risk helminth infection , residence within recent travel ( within 12 month baseline visit ) area endemic endoparasitoses , circumstance consistent parasite exposure ( eg , extended stay , rural slum area , lack run water , consumption uncooked , undercooked , otherwise potentially contaminate food , close contact carrier vector , etc ) , unless subsequent medical assessment ( eg , stool exam , blood test , etc ) rule possibility parasite infection/infestation 17 . Female patient pregnant , breastfeeding , plan become pregnant breastfeed study 18 . Women use form hormonal contraceptive ( eg , oral , injectables , implant , patch , ring , hormoneimpregnated intrauterine device [ IUDs ] ) birth control 19 . Women unwilling use adequate birth control , reproductive potential sexually active .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>